Elevated FOSB-expression; a potential marker of valproate sensitivity in AML

British Journal of Haematology

Volumn 144, Issue 3, 2009, Pages 332-341

  Khanim, Farhat L ^a   Bradbury, Charlotte A ^b   Arrazi, Julie ^b   Hayden, Rachel E ^a   Rye, Adam ^c   Basu, Supratik ^d   MacWhannell, Alan ^d   Sawers, Alistair ^e   Griffiths, Michael ^f   Cook, Mark ^g   Freeman, Sylvie ^b   Nightingale, Karl P ^b   Grimwade, David ^h   Falciani, Francesco ^b   Turner, Bryan M ^b   Bunce, Chris M ^a   Craddock, Charles ^g  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^c CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^d NEW CROSS HOSPITAL   (United Kingdom)

^e WORCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^f BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^g QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Clinical trial; FOSB; HDAC inhibitor; Sodium valproate

Indexed keywords

RETINOIC ACID; THEOPHYLLINE; TRANSCRIPTION FACTOR FOSB; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOID CELL LINE; MALE; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-FOS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VALPROIC ACID;

EID: 58449117136     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07449.x     Document Type: Article

References (45)

1. Altucci, L., Rossin, A., Hirsch, O., Nebbioso, A., Vitoux, D., Wilhelm, E., Guidez, F., De Simone, M., Schiavone, E.M., Grimwade, D., Zelent, A., de The, H. Gronemeyer, H. (2005) Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Research, 65, 8754 8765.
2. Arts, J., Angibaud, P., Marien, A., Floren, W., Janssens, B., King, P., van Dun, J., Janssen, L., Geerts, T., Tuman, R.W., Johnson, D.L., Andries, L., Jung, M., Janicot, M. van Emelen, K. (2007) R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. British Journal of Cancer, 97, 1344 1353.
3. Asghari, V., Wang, J.F., Reiach, J.S. Young, L.T. (1998) Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Molecular Brain Research, 58, 95 102.
4. Bamberger, A.M., Methner, C., Lisboa, B.W., Stadtler, C., Schulte, H.M., Loning, T. Milde-Langosch, K. (1999) Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. International Journal of Cancer, 84, 533 538.
5. Bradbury, C.A., Khanim, F.L., Hayden, R., Bunce, C.M., White, D.A., Drayson, M.T., Craddock, C. Turner, B.M. (2005) Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia, 19, 1751 1759.
6. Brunello, N. Tascedda, F. (2003) Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders. International Journal of Neuropsychopharmacology, 6, 181 189.
7. Bruserud, O., Stapnes, C., Ersvaer, E., Gjertsen, B.T. Ryningen, A. (2007) Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Current Pharmaceutical Biotechnology, 8, 388 400.
8. Bug, G., Ritter, M., Wassmann, B., Schoch, C., Heinzel, T., Schwarz, K., Romanski, A., Kramer, O.H., Kampfmann, M., Hoelzer, D., Neubauer, A., Ruthardt, M. Ottmann, O.G. (2005) Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer, 104, 2717 2725.
9. Cai, D., Wang, Y., Ottmann, O.G., Barth, P.J., Neubauer, A. Burchert, A. (2006) FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment. Blood, 107, 2094 2097.
10. Cao, Z.A., Bass, K.E., Balasubramanian, S., Liu, L., Schultz, B., Verner, E., Dai, Y., Molina, R.A., Davis, J.R., Misialek, S., Sendzik, M., Orr, C.J., Leung, L., Callan, O., Young, P., Dalrymple, S.A. Buggy, J.J. (2006) CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo. Molecular Cancer Therapeutics, 5, 1693 1701.
11. Chen, L.F. Greene, W.C. (2003) Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. Journal of Molecular Medicine, 81, 549 557.
12. Chen, J., Ghazawi, F.M., Bakkar, W. Li, Q. (2006) Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Molecular Cancer, 5, 71.
13. Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Lowenberg, B., Sanz, M.A., Head, D.R., Ohno, R. Bloomfield, C.D. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 21, 4642 4649.
14. Cimino, G., Lo-Coco, F., Fenu, S., Travaglini, L., Finolezzi, E., Mancini, M., Nanni, M., Careddu, A., Fazi, F., Padula, F., Fiorini, R., Spiriti, M.A., Petti, M.C., Venditti, A., Amadori, S., Mandelli, F., Pelicci, P.G. Nervi, C. (2006) Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Research, 66, 8903 8911.
15. Falschlehner, C., Emmerich, C.H., Gerlach, B. Walczak, H. (2007) TRAIL signalling: decisions between life and death. International Journal of Biochemistry and Cell Biology, 39, 1462 1475.
16. Ferrara, F.F., Fazi, F., Bianchini, A., Padula, F., Gelmetti, V., Minucci, S., Mancini, M., Pelicci, P.G., Lo Coco, F. Nervi, C. (2001) Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Research, 61, 2 7.
17. Fiskus, W., Ren, Y., Mohapatra, A., Bali, P., Mandawat, A., Rao, R., Herger, B., Yang, Y., Atadja, P., Wu, J. Bhalla, K. (2007) Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clinical Cancer Research, 13, 4882 4890.
18. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O.H., Schimpf, A., Giavara, S., Sleeman, J.P., Lo Coco, F., Nervi, C., Pelicci, P.G. Heinzel, T. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. The EMBO Journal, 20, 6969 6978.
19. Gui, C.Y., Ngo, L., Xu, W.S., Richon, V.M. Marks, P.A. (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proceedings of the National Academy of Sciences of the United States of America, 101, 1241 1246.
20. He, L.Z., Tolentino, T., Grayson, P., Zhong, S., Warrell, R.P. Jr., Rifkind, R.A., Marks, P.A., Richon, V.M. Pandolfi, P.P. (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. Journal of Clinical Investigation, 108, 1321 1330.
21. Hegde, P., Qi, R., Abernathy, K., Gay, C., Dharap, S., Gaspard, R., Hughes, J.E., Snesrud, E., Lee, N. Quackenbush, J. (2000) A concise guide to cDNA microarray analysis. Biotechniques, 29, 548 550, 552-544, 556 passim.
22. Hess, J., Angel, P. Schorpp-Kistner, M. (2004) AP-1 subunits: quarrel and harmony among siblings. Journal of Cell Science, 117, 5965 5973.
23. Iacomino, G., Medici, M.C. Russo, G.L. (2008) Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis. Anticancer Research, 28, 855 864.
24. Insinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S. Pelicci, P.G. (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Medicine, 11, 71 76.
25. Konstantinopoulos, P.A., Vandoros, G.P. Papavassiliou, A.G. (2006) FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemotherapy and Pharmacology, 58, 711 715.
26. Kuendgen, A., Schmid, M., Schlenk, R., Knipp, S., Hildebrandt, B., Steidl, C., Germing, U., Haas, R., Dohner, H. Gattermann, N. (2006) The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer, 106, 112 119.
27. McGarry, L.C., Winnie, J.N. Ozanne, B.W. (2004) Invasion of v-Fos(FBR)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes. Oncogene, 23, 5284 5292.
28. Milde-Langosch, K. (2005) The Fos family of transcription factors and their role in tumourigenesis. European Journal of Cancer, 41, 2449 2461.
29. Mitsiades, C.S., Mitsiades, N., Poulaki, V., Schlossman, R., Akiyama, M., Chauhan, D., Hideshima, T., Treon, S.P., Munshi, N.C., Richardson, P.G. Anderson, K.C. (2002) Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene, 21, 5673 5683.
30. Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Alvarez, R., Schiavone, E.M., Ferrara, F., Bresciani, F., Weisz, A., de Lera, A.R., Gronemeyer, H. Altucci, L. (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Medicine, 11, 77 84.
31. Nishioka, C., Ikezoe, T., Yang, J., Takeuchi, S., Koeffler, H.P. Yokoyama, A. (2008) MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leukemia Research, 32, 1382 1392.
32. O'Connor, O.A., Heaney, M.L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., Zelenetz, A.D., Frankel, S., Richon, V., Marks, P. Kelly, W.K. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. Journal of Clinical Oncology, 24, 166 173.
33. Pilatrino, C., Cilloni, D., Messa, E., Morotti, A., Giugliano, E., Pautasso, M., Familiari, U., Cappia, S., Pelicci, P.G., Lo Coco, F., Saglio, G. Guerrasio, A. (2005) Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer, 104, 101 109.
34. Qian, D.Z., Kato, Y., Shabbeer, S., Wei, Y., Verheul, H.M., Salumbides, B., Sanni, T., Atadja, P. Pili, R. (2006) Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clinical Cancer Research, 12, 634 642.
35. Raffoux, E., Chaibi, P., Dombret, H. Degos, L. (2005) Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica, 90, 986 988.
36. Rosenberg, G. (2007) The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cellular and Molecular Life Sciences, 64, 2090 2103.
37. Schuermann, M., Jooss, K. Muller, R. (1991) fosB is a transforming gene encoding a transcriptional activator. Oncogene, 6, 567 576.
38. Smith, C.L. (2008) A shifting paradigm: histone deacetylases and transcriptional activation. Bioessays, 30, 15 24.
39. Stapnes, C., Ryningen, A., Hatfield, K., Oyan, A.M., Eide, G.E., Corbascio, M., Kalland, K.H., Gjertsen, B.T. Bruserud, O. (2007) Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. International Journal of Oncology, 31, 1529 1538.
40. Szot, P., White, S.S., Shen, D.D. Anderson, G.D. (2005) Valproic acid, but not lamotrigine, suppresses seizure-induced c-fos and c-Jun mRNA expression. Molecular Brain Research, 135, 285 289.
41. Tallman, M.S. (2007) Treatment of relapsed or refractory acute promyelocytic leukemia. Best Practice & Research Clinical Haematology, 20, 57 65.
42. Wajant, H. (2004) TRAIL and NFkappaB signaling-a complex relationship. Vitamins and Hormones, 67, 101 132.
43. White, D.A., Belyaev, N.D. Turner, B.M. (1999) Preparation of site-specific antibodies to acetylated histones. Methods, 19, 417 424.
44. Yang, Y., Rao, R., Shen, J., Tang, Y., Fiskus, W., Nechtman, J., Atadja, P. Bhalla, K. (2008) Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Research, 68, 4833 4842.
45. Zhang, X., Zhang, L., Yang, H., Huang, X., Otu, H., Libermann, T.A., DeWolf, W.C., Khosravi-Far, R. Olumi, A.F. (2007) c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Research, 67, 9425 9434.